Observatorio de I+D+i UPM

Go Back | Technology Solutions

OPHTALMOLOGIC KIT. Reducing risks in the retinal detachment treatment

More info

[OphtalmologicKit]Commercial_sheet_UPM_EN(Innovatech) PDF
 
Briefing

Patented ocular device that optimizes the accuracy of retinal detachment surgical operations, reducing risks and improving patient well-being

A research group of the Center of Biomedical Technology (CTB) at the Technical University of Madrid (UPM) has developed an innovative solution to improve the efficiency of the retinal detachment surgery, both potential medical costs resulting from the treatment and patients welfare, in collaboration with researchers and doctors of University Hospital Ramón y Cajal, Universidad Autónoma de Madrid and the Biomedical Research Networking center in Bioengineering, Biomaterials and Nanomedicine. Applying nanotechnology in the field of biomedicine, this patented device has already been successfully tested in animals with a success rate over 80%, proving the expected benefits in terms of reducing the likelihood of new surgical operations, side effects and post-surgical recovery time. The global market for ophthalmologic surgical equipment is expected to increase to 7.300 M€ in 2014, an average compound annual growth rate of 6% during the last few years.

 
Technology Solution

Retinal detachment solutionThis solution provides a magnetic ocular implant, a ferrofluid and a methodology for using in the retinal detachment treatment and other eye disorders. Magnetic nanoparticles, wich remain in suspension in this ferrofluid, are used as a tamponade agent after their intraocular injection  and location in the outer layer of the eye through magnetic field.

 

The appropriate dosage and introduction of ferrofluid, which interacts magnetically with the implant, allows a more reliable and adequate arrangement of the retina after its detachment, reducing risk of side effects and additional operations and shortening the post-surgical recovery time.

 

 

"A new worlwide ocular device applying nanotechnologies to improve both retinal detachment surgery performance and patient welfare"

 
Market demands

  • The rapidly population aging leads to a fast population growth over 65 years, the sector with the highest incidence of eye diseases and disorders [BBC Research].
  • High incidence of retinal detachment (epidemiological approaches indicate one case per 10.000 population per year): this surgical operation is one of the most common ophthalmological procedures.
  • Around 50% of these cases need to have a second surgical procedure.
  • Need for specific and uncomfortable patient positionings during the most common surgery: eye incisions for the retina reattachment and later injection of substance for sealing off the hole after detachment.
  • Alternative solutions (gas or silicone retinal tamponade agents after surgery) have significant side effects and could lead to medical complications: risk factors for retinal re-detachment because of a very specific rehabilitation protocol in terms of patient positionings.

“Ophthalmologic procedures require millimeter precision and  are needed for real advances in the surgical equipment… a healthcare industry that would reach 7.300 M€ in 2014”

 
Market potential

  • Changing trends in diets, lifestyle, and increased longevity are growing the global market for opthalmic devices and treatments: it is expected to reach 28.000 M$ in 2016, with a compound annual growth rate (CAGR) of 2.5% until 2016. Surgical procedures currently respresents a leading division for this industry [GBI Research].
  • By 2014, ophthalmic surgical equipment industry would be valued at 7.300 M€, a CAGR of 5,9% [BCC Research]
  • 3 priority healthcare areas impacted by this solution: electromedical and medical technology; medical and surgical materiales; and prostheses and implants.
  • In Europe, medical technology market size is estimated at 100 B€, employing 575.000 people and being driven by 25.000 medtech companies, tha majority of which, around 95%, are small and micro-sized companies [Eucomed and EuroStat].

 

Retinal detachment Ophtalmic industry
 
Competitive advantages

  • Increase retinal detachment surgery and other eye disorders treatment success rate: medical and surgical equipment cost savings.
  • Increase patient comfort and safety after the operation: higher tamponade agent placement accuracy in the retinal detachment area and lower risk of side effects such as cataracts or inflammation.
  • Device already tested in animals with a success rate over 80%.
  • Additional use as a surgical aid auxiliary (subretinal fluid drainage).
  • Ability to place other substances into the device (drugs, proteins ...) in order to shorten the patient recovery time or protect him from infections.
 
References

 
IPR

 
Development stage

  • Concept
  • R&D
  • Lab-Protoype
  • Industrial Prototype
  • Production
 
Contact

Ophtalmologic Kit UPM contact

José Javier Serrano Olmedo

Center of Biomedical Technology (CTB) - UPM

e: josejavier.serrano@upm.es

w: http://www.ctb.upm.es

UPM contact

Innovation, Commercialization and Entrepreneurship Area

Centre of Support for Technological Innovation - UPM

e: innovacion.tecnologica@upm.es

 
S2i 2019 Observatorio de investigación @ UPM con la colaboración del Consejo Social UPM
Cofinanciación del MINECO en el marco del Programa INNCIDE 2011 (OTR-2011-0236)
Cofinanciación del MINECO en el marco del Programa INNPACTO (IPT-020000-2010-22)